Daniel A. Morgenstern

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.

Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.

Journal: JCO precision oncology

Published: August 01, 2025

Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer.

Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 29, 2025

Early phase study enrollment in Canadian children with cancer near end of life: A retrospective cohort study from Cancer in Young People in Canada.

Early phase study enrollment in Canadian children with cancer near end of life: A retrospective cohort study from Cancer in Young People in Canada.

Journal: Cancer

Published: April 18, 2025

Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study.

Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study.

Journal: Pediatric blood & cancer

Published: April 11, 2025

Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.

Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 03, 2025

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.

Journal: Pediatric blood & cancer

Published: February 26, 2025

Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.

Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 14, 2025

Comment on: Incidence of Adrenal Insufficiency in Patients with High-Risk Neuroblastoma: A Single-Institution Analysis.

Comment on: Incidence of Adrenal Insufficiency in Patients with High-Risk Neuroblastoma: A Single-Institution Analysis.

Journal: Pediatric blood & cancer

Published: January 28, 2025

Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.

Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 27, 2025

Assessing the Impact of u-link.care: Implementation of a Pediatric Cancer Clinical Trials Finder Website to Improve Healthcare Provider Knowledge and Identify Barriers to Enrollment.

Assessing the Impact of u-link.care: Implementation of a Pediatric Cancer Clinical Trials Finder Website to Improve Healthcare Provider Knowledge and Identify Barriers to Enrollment.

Journal: Pediatric blood & cancer

Published: January 15, 2025

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.

Journal: Pediatric blood & cancer

Published: November 21, 2024

Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.

Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.

Journal: Pediatric blood & cancer

Published: November 14, 2024

Showing 1-12 of 64

Last Updated: 09/26/2026